search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Breast Reconstruction In One Stage


- candidate number22958
- NTR NumberNTR5446
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR8-okt-2015
- Secondary IDsPRHC-2012-RS01-version 4 
- Public TitleBreast Reconstruction In One Stage
- Scientific TitleSkin sparing mastectomy with implant reconstruction: clinical outcomes and cost effectiveness of reconstruction in one stage with the use of a collagen matrix. A randomized clinical trial.
- ACRONYMBRIOS Study
- hypothesisThe aim of this study is to compare clinical outcomes and cost-effectiveness of two procedures for skin sparing mastectomy with implant reconstruction in a randomized clinical trial. The currently preferred two-stage breast reconstruction with implantation of a tissue expander during a first, and placement of a breast prosthesis during a second surgery will be compared to the novel one-stage immediate breast reconstruction, where implants are combined with a collagen matrix inlay (Strattice™).

The use of a collagen matrix in combination with definitive implants in immediate breast reconstruction after skin sparing mastectomy is a good one-stage alternative for the traditional two-stage procedure because we think it
I. has the same or a lower complication rate;
II. gives equal or a better cosmetic result;
III. is less painful to the patient;
IV. Is more cost-effective.
- Healt Condition(s) or Problem(s) studiedMastectomy, Breast reconstruction
- Inclusion criteriaFemales are included if they meet the following criteria:
▪ women with the BRCA 1/2 gen mutation who will undergo prophylactic treatment
▪ intended to undergo a skin sparing mastectomy
▪ willing and able to participate;
▪ aged 18 and over;
▪ able to provide informed consent and
▪ able to complete questionnaires.
- Exclusion criteriaExclusion criteria are:
▪ women with a body mass index > 30
▪ woman who need a too large breast size according to the specialist
▪ woman who receive a polyurethaan implant
▪ women who did not quit smoking two weeks before surgery
▪ oncologic patients who have to receive post-operative radiotherapy
▪ pregnancy or planning a pregnancy during the study;
▪ ongoing severe psychiatric illness or mental retardation;
▪ evidence of alcohol and/or drug abuse;
▪ inability to complete the questionnaires;
▪ local or general infection which could jeopardize the surgical objective;
▪ extensive local inflammatory reactions;
▪ proven or suspected hypersensitivity to materials;
▪ immunosuppressive pathologies.
- mec approval receivedyes
- multicenter trialyes
- randomisedyes
- masking/blindingNone
- controlActive
- groupParallel
- Type2 or more arms, randomized
- Studytypeobservational
- planned startdate 1-mei-2013
- planned closingdate1-jun-2016
- Target number of participants140
- InterventionsPatients whom are eligible for the study and give informed consent will be operated by a plastic surgeon. Skin sparing mastectomy and implant reconstruction will be performed in all patients. Patients will be randomized to treatment group 1 or 2 three days before the mastectomy. In treatment group 1 a tissue expander will be placed during a first surgery, and abreast prosthesis will be placed during a second surgery. In the time between the first and second surgery the tissue expander will be filled repeatedly.
In treatment group 2, patients will undergo a skin sparing mastectomy with immediate placement of a breast implant combined with a collagen matrix sheet (Strattice™).
- Primary outcomeThe primary endpoint of the study is the quality of life as measured by a specific breast related questionnaire (BREAST-Q) at one year after placement of the permanent prosthesis. This questionnaire was elected because it is especially suitable and valid for the post-mastectomy population.
- Secondary outcomeComplication rate (e.g. infection, implant loss, seroma, contraction of the breast), aesthetic outcome (as measured by a panel of experts at one year after placement of the permanent prosthesis), pain, and patient burden with regard to the number of procedures and time invested are secondary outcomes.
- TimepointsThe follow-up moments will be arranged as following:
One-step procedure:
Surgery - 2 weeks post-op - 6 weeks – 3 months - 6 months – 12 months post-op.
Two-step procedure:
Tissue Expander - Fillings – Implant – 2 weeks – 6 weeks – 3 months - 6 months – 12 months post-op.
- Trial web sitewww.vumc.nl/brios
- statusinclusion stopped: follow-up
- CONTACT FOR PUBLIC QUERIESPhD-candidate Rieky E. Dikmans
- CONTACT for SCIENTIFIC QUERIESPhD-candidate Rieky E. Dikmans
- Sponsor/Initiator VU University Medical Center
- Funding
(Source(s) of Monetary or Material Support)
Pink Ribbon, Nuts/Ohra, LifeCell
- Publications
- Brief summary
- Main changes (audit trail)
- RECORD8-okt-2015 - 22-nov-2015


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl